# 2026-16440: NIH's Clot-Busting Antibodies Free for Cancer-COVID License

2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions, is a Federal Register notice from Health and Human Services Department, National Institutes of Health published 2026-08-12, effective 2026-08-12; PRIA reads it as touching household money (as of 2026-08-19).

- Canonical: https://policyrisk.com/federal-register/2026-16440
- As of: 2026-08-19
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-16440
- Title: NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
- Type: Notice
- Agencies: Health and Human Services Department; National Institutes of Health
- Citation: 91 FR 52066
- Published: 2026-08-12
- Effective: 2026-08-12
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-08-19

## In one line

NIH's Clot-Busting Antibodies Free for Cancer-COVID License

## Summary

Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.

## Effects PRIA read

- NCI Offering sTF Licensing Opportunity: benefit, medium. The National Cancer Institute (NCI) is offering its soluble tissue factor (sTF) humanized monoclonal antibodies and related diagnostic and therapeutic methods for licensing or collaborative development. Partnership opportunities explicitly include preclinical optimization, clinical development, and…
- Potentially More Accurate Thrombosis Test: benefit, medium. The NCI describes soluble tissue factor (sTF) as offering a much more sensitive and specific test of thrombosis than the current D-dimer test. This discovery is presented as a basis for diagnostic tools such as ELISA and point-of-care assays for earlier detection and monitoring of thrombosis.
- Safer Anti-Thrombosis Therapeutic Approach: benefit, medium. NCI reports humanized monoclonal antibodies that selectively neutralize soluble tissue factor (sTF) can block pathological thrombosis without systemic anticoagulation and while preserving normal hemostasis. The notice describes in vivo validation showing prevention of fibrinogen depletion and norma…

## Related documents

- [2026-22871](https://policyrisk.com/federal-register/2026-22871): Center for Scientific Review; Notice of Closed Meetings, 2026-11-10
- [2026-22550](https://policyrisk.com/federal-register/2026-22550): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22558](https://policyrisk.com/federal-register/2026-22558): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22339](https://policyrisk.com/federal-register/2026-22339): Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human, 2026-11-02
- [2026-22196](https://policyrisk.com/federal-register/2026-22196): National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting, 2026-10-30
- [2026-22111](https://policyrisk.com/federal-register/2026-22111): Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting, 2026-10-29

## Sources
- [2026-16440 on federalregister.gov](https://www.federalregister.gov/documents/2026/08/12/2026-16440/nih-owned-invention-available-for-license-soluble-tissue-factor-a-novel-target-and-antibodies-for)
- [2026-16440 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16440.pdf)

## Related
- [Previous: 2026-16439, Government Owned Invention Available for License: Quantitative Particle Identif…](https://policyrisk.com/federal-register/2026-16439)
- [Next: 2026-16441, Government Owned Invention Available for License: DNA Methylation-Based Cancer…](https://policyrisk.com/federal-register/2026-16441)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-16440 (as of 2026-08-19).